Free Newsletter
SPOTLIGHT: Barr, Novartis in Ritalin LA patent fight
Free newsletter via e-mail
Tools
Barr Pharmaceuticals is challenging Novartis' patent on the attention deficit hyperactivity drug Ritalin LA, which sold $109 million worth in the U.S. for the year ending in August. The Swiss drug maker filed suit against Barr Friday, hoping to keep the generics firm from taking its version of the product to market. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
